Marketing: Page 2

Can digital therapeutics be profitable?

Licensing deals with pharmaceutical companies were an early strategy for digital health companies, but not all of them have lasted.

By Elise Reuter • April 11, 2022

The power of alerts

As medical affairs continues to invest in systems and data, it can quickly become overwhelming to keep up with it all.

April 11, 2022

Medicare finalizes policy limiting coverage of Biogen Alzheimer's drug

Biogen said it is considering its options following CMS' decision, which restricts reimbursement of Aduhelm to patients enrolled in a randomized clinical trial. 

By Jonathan Gardner • Updated April 7, 2022

A new approach for post-marketing safety studies

The large quantity of digitized healthcare data in the U.S. presents an enormous opportunity to shift dramatically how post-marketing safety studies can and should be conducted.

By Stefan Weiss, MD, MHSc, MBA, Managing Director of Dermatology, OM1 • April 4, 2022

Two decades and $200 billion: AbbVie's Humira monopoly nears its end

Biosimilar copies of Humira will arrive in the U.S. beginning early next year, testing both AbbVie and the market potential for knockoff biologic drugs.

By Jonathan Gardner • March 17, 2022

Akili, with plans to go public, prepares to ramp up marketing of video game treatment

"We've proven that foundation and now it's time to run and scale," said CEO Eddie Martucci. The company is going public through a $1 billion SPAC, rather than a traditional IPO.

By Elise Reuter • March 10, 2022

AbbVie holds off another Humira challenger with Alvotech deal

A settlement will allow the Iceland-based drugmaker to launch its Humira copycat, currently under FDA review, in the U.S. beginning next July.

By Ned Pagliarulo • March 9, 2022

Novo sees fast growth ahead of obesity drugs despite production hurdles

The Danish drugmaker aims to triple sales of its weight loss treatments Wegovy and Saxenda by 2025. But first, Novo needs to resolve manufacturing constraints that have slowed the former drug's launch. 

By Ned Pagliarulo • March 4, 2022

Sanofi partners with digital health company DarioHealth

The deal with DarioHealth is one of several digital health investments by the French pharma company in recent years, although not all have panned out.

By Elise Reuter • March 2, 2022

Moderna sued for allegedly infringing patents tied to COVID-19 vaccine

Arbutus and partner Genevant claim Moderna's coronavirus shot uses delivery technology covered by six patents they hold, an allegation Moderna denies. 

By Ned Pagliarulo • Feb. 28, 2022

FTC deadlocks on vote to launch study into PBM practices

The antitrust agency won't study pharmacy benefit managers' pricing and contract practices as proposed, after a 2-2 vote by commissioners Thursday.

By Samantha Liss • Feb. 17, 2022

Seagen shares sink as sales outlook of cancer drug disappoints

The biotech is predicting sales of Tukysa, its new breast cancer drug, will remain flat or fall in 2022 as competition increases from AstraZeneca's rival medicine Enhertu.

By Jacob Bell • Feb. 10, 2022

Amgen expects rising sales through 2030, but Wall Street still has doubts

Facing falling sales of top-seller Enbrel, the biotech tried to shore up confidence in its ability to grow new products, like the cancer drug Lumakras.

By Kristin Jensen • Feb. 9, 2022

Biogen buys into fast-advancing Roche cancer drug

The biotech will pay $30 million to opt into rights for mosunetuzumab, a bispecific antibody that Roche has developed for non-Hodgkin's lymphoma.

By Ned Pagliarulo • Feb. 1, 2022

Medicare faces blowback over plan to limit coverage of Biogen's Alzheimer's drug

Biogen, along with allies in industry, plans to pressure Medicare to water down its policy, which limits coverage of Aduhelm and drugs like it to clinical trials.

By Jonathan Gardner , Jacob Bell • Jan. 14, 2022

Medicare proposes to limit coverage of Biogen Alzheimer's drug

The program will only cover Aduhelm, which the FDA controversially approved last June, for patients enrolled in rigorous clinical trials, likely forestalling broader adoption of the treatment.

By Jonathan Gardner , Jacob Bell • Updated Jan. 11, 2022

Novartis wins FDA approval for new heart drug, but faces uphill sales battle

Leqvio, which Novartis acquired for nearly $10 billion two years ago, arrives with high sales expectations. But uptake could be slow as insurers and doctors weigh the drug's safety and cost-effectiveness.

By Jonathan Gardner • Dec. 22, 2021

After intense pushback, Biogen to cut price of Alzheimer's drug

Effective Jan. 1, the average list price for Aduhelm will drop about 50% to just over $28,000 a year. It's a move the company hopes will appease insurers and lower out-of-pocket costs for patients.

By Jacob Bell • Dec. 20, 2021

European regulators say no to Aduhelm, but Biogen is pushing back

The company plans to ask the European Medicines Agency to reexamine its conclusion that "the benefits of Aduhelm do not outweigh its risks."

By Jacob Bell • Dec. 17, 2021

J&J's coronavirus vaccine faces new US limits

Days after the FDA strengthened safety warnings for J&J's shot, a CDC panel recommended Pfizer's and Moderna's vaccines be "preferred."

By Jonathan Gardner • Updated Dec. 17, 2021

Humana, Centene sue drugmakers, alleging anticompetitive practices on HIV drugs

The insurers filed suit against Gilead, J&J, Bristol Myers Squibb and Teva, claiming the drugmakers conspired to protect lucrative HIV drugs from competition.

By Rebecca Pifer • Dec. 14, 2021

AbbVie's blockbuster weighed down by safety concerns for a similar Pfizer drug

Like Pfizer's Xeljanz, the label for AbbVie's Rinvoq has been updated to warn about risks of death and major cardiovascular events like stroke.

By Jacob Bell • Dec. 6, 2021

Audience targeting in a changing digital landscape

How will your digital advertising strategy evolve in a future without cookies?

Dec. 6, 2021

Anticipating Aduhelm's costs, Medicare plans big jump in premiums

While CMS is still weighing whether to authorize wide coverage of Biogen's pricey Alzheimer's drug, administrators are planning to build reserves in case costs skyrocket.

By Jonathan Gardner • Nov. 15, 2021

IQVIA Omnichannel Navigator: A platform for informing smarter marketing decisions

This year, the pharmaceutical industry will spend more on its promotional activities than any year before. It’s estimated that the total U.S. promotional spend for 2021 will be around $30 billion.

By Kathryn Grimshaw • Nov. 8, 2021